HEC, Lannet Eye US Generic Insulin Market Through Extended Alliance
This article was originally published in PharmAsia News
Following bilateral distribution and contract manufacturing agreements signed in 2014, China’s HEC Pharm and Lannett have extended their partnership for generic insulin glargine development to the US market. Clinical trial applications have been filed in China and HEC expects generic insulins to give more impetus to its business growth after 2018.
Register for our free email digests: